Vyleesi™ (bremelanotide) – New drug approval
June 21, 2019 - The FDA announced the approval of AMAG Pharmaceuticals’ Vyleesi (bremelanotide), for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.
Top